ITI Pharma and Healthcare Fund
ITI Mutual Fund · Sectoral/Thematic · Regular plan, growth option
NAV (₹), 2 Oct 2026
17.6281
1-day change
-0.20%
1Y return
10.4%
3Y CAGR
16.7%
5Y CAGR
n/a
Max drawdown, 5Y
n/a
NAV history month-end NAV, ₹ · 11 Nov 2021 to 1 Oct 2026
Returns vs Sectoral/Thematic median (259 schemes) and “Healthcare & pharma” median (19)
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -3.2% | -5.4% | -3.2% |
| 3 months | 2.1% | -3.1% | 2.7% |
| 6 months | 19.1% | 8.5% | 21.0% |
| Year to date | 12.3% | -2.6% | 16.3% |
| 1 year | 10.4% | 0.0% | 16.0% |
| 3 years (CAGR) | 16.7% | 11.7% | 19.2% |
| 5 years (CAGR) | n/a | 10.6% | 13.7% |
| 7 years (CAGR) | n/a | 15.7% | 23.7% |
| 10 years (CAGR) | n/a | 13.3% | 13.4% |
| Since first NAV (CAGR) | 12.3% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
Rolling returns every business-day start date
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 13.8% | 9.8% |
| 3Y rolling median | 19.1% | 15.6% |
| 3Y rolling worst | 15.2% | 0.6% |
| 3Y periods positive | 100% | 100% |
| 3Y periods ahead of benchmark | 99% | 71% |
| 5Y rolling median | n/a | 14.2% |
| 5Y rolling worst | n/a | 0.3% |
| 5Y periods ahead of benchmark | n/a | 70% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
Risk 36 months, monthly returns, Rf 6.5%
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 16.5% | 16.7% |
| Sharpe ratio | 0.71 | 0.34 |
| Sortino ratio | 1.13 | 0.51 |
| Beta | 0.79 | 0.96 |
| Alpha (ann.) | 9.0% | 2.3% |
| Upside capture | 114.08 | 103.56 |
| Downside capture | 76.68 | 96.87 |
Drawdowns peak-to-trough falls in NAV
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −18.5% | −23.7% |
| Maximum drawdown, last 10Y | n/a | −39.3% |
| Maximum drawdown, last 5Y | n/a | −22.8% |
| Current drawdown | −4.4% | −8.8% |
| Recovery time of worst fall | 384 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
Cost, size and riskometer as disclosed to AMFI
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Regular plan | 2.59% | 2.65% |
| AUM, whole scheme (₹ crore) | 266 | 1,245 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
Official benchmark and category consistency
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 11.9% | 14.7% TRI |
| Return, 3 years (AMFI) | 16.7% | 19.0% TRI |
| Month-ends above category median (3Y CAGR) | 96% | 53% median |
| Month-ends in category top quartile (3Y) | 4% | 24% median |
Official benchmark: NIFTY Healthcare TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Sectoral/Thematic Regular plans; how it is calculated.
Calendar-year returns NAV change from 31 Dec to 31 Dec
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 12.3% | -7.8% | +20.1% |
| 2025 | -10.0% | 7.7% | −17.6% |
| 2024 | 41.3% | 15.6% | +25.6% |
| 2023 | 31.6% | 26.5% | +5.1% |
| 2022 | -8.7% | 3.8% | −12.5% |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
Monthly SIP of ₹10,000 first business day of each month, ending 2 Oct 2026
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,30,552 | 16.7% |
| 3 years | ₹3,60,000 | ₹4,22,910 | 10.7% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
Scheme facts
AMC: ITI Mutual Fund
Category: Sectoral/Thematic
Plan / option: Regular · Growth
AMFI scheme code: 149270
ISIN: INF00XX01BL5
First NAV in MFIC data: 11 Nov 2021
History: 4.9 years
Expense ratio, AUM, portfolio: see the scheme's factsheet
Schemes that behaved similarly correlation of monthly returns, last 5 years
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| UTI - Healthcare Fund | Sectoral/Thematic | 0.97 | 21.4% |
| HDFC Pharma and Healthcare Fund | Sectoral/Thematic | 0.97 | 28.6% |
| LIC MF Healthcare Fund | Sectoral/Thematic | 0.97 | 19.4% |
| Tata India Pharma & Healthcare Fund | Sectoral/Thematic | 0.97 | 16.5% |
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.97 | 20.0% |
| Kotak Healthcare Fund | Sectoral/Thematic | 0.96 | n/a |
Questions about ITI Pharma and Healthcare Fund
- What is the latest NAV of ITI Pharma and Healthcare Fund?
- The NAV of the Regular plan (growth option) was ₹17.6281 on 2 Oct 2026, as published by AMFI.
- Which category is ITI Pharma and Healthcare Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 259 Sectoral/Thematic schemes (Regular plans).
- What returns has ITI Pharma and Healthcare Fund delivered?
- Over one year the NAV changed by 10.4%. The 3-year CAGR is 16.7% (category median 11.7%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 19.1%, the lowest was 15.2%, and 100% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 99% of those periods.
- What was the largest fall in ITI Pharma and Healthcare Fund's NAV?
- The largest peak-to-trough fall in its available history was 18.5%.
- How volatile is ITI Pharma and Healthcare Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 16.5%, which is below the Sectoral/Thematic category median of 16.7%.
- What would a monthly SIP in ITI Pharma and Healthcare Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 3 years (36 instalments, ₹3,60,000 invested) would have been worth about ₹4,22,910 on 2 Oct 2026, an annualised return (XIRR) of 10.7%. This uses the Regular plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of ITI Pharma and Healthcare Fund?
- The total expense ratio of the Regular plan is 2.59% a year, as disclosed to AMFI (median of Sectoral/Thematic Regular plans: 2.65%). It is already deducted from the NAV, so every return shown is after expenses.
- How large is ITI Pharma and Healthcare Fund?
- Assets under management of the whole scheme were ₹266 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of ITI Pharma and Healthcare Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of ITI Pharma and Healthcare Fund and how has it compared?
- Its official benchmark is the NIFTY Healthcare TRI. Over 3 years AMFI reports a return of 16.7% for this plan against 19.0% for the benchmark total return index. Past performance does not indicate future results.
- How often has ITI Pharma and Healthcare Fund beaten its category?
- At 96% of the 23 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Regular plans); it was in the top quarter at 4% of them. A typical scheme would show about 50%.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 12.4% and the Regular plan's by 10.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow ITI Pharma and Healthcare Fund by email
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.
Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 2 Oct 2026. Category medians use Regular plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.